Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study

Autor: Goepfert, Paul A, Fu, Bo, Chabanon, Anne-Laure, Bonaparte, Matthew I, Davis, Matthew G, Essink, Brandon J, Frank, Ian, Haney, Owen, Janosczyk, Helene, Keefer, Michael C, Koutsoukos, Marguerite, Kimmel, Murray A, Masotti, Roger, Savarino, Stephen J, Schuerman, Lode, Schwartz, Howard, Sher, Lawrence D, Smith, Jon, Tavares-Da-Silva, Fernanda, Gurunathan, Sanjay, DiazGranados, Carlos A, de Bruyn, Guy *
Zdroj: In The Lancet Infectious Diseases September 2021 21(9):1257-1270
Databáze: ScienceDirect